Abstract
The outbreak of the COVID-19 epidemic is a breach of health protection worldwide. Complications in people who limit the risk of COVID-19 can be associated with physical and mental health. Identification of states associated with anxiety and depression and threats that may occur in patients after COVID-19 is a very important aspect that occurs on the selection of therapeutic methods, and thus recovery occurs. The aim of the study was to assess the penalty in the treatment of anxiety symptoms and depressiveness in a patient after COVID-19. The study includes the effects resulting from brain-derived neurotrophic factor, irisin and other problems related to problems and depressive symptoms in patients after COVID-19. included in the study participation in the rehabilitation education program in stationary conditions. The Generalized Anxiety Disorder Questionnaire was used to solve anxiety problems. The Beck Depression Inventory was used to assess the effects of depression. To assess the update of the irisin (ng/mL) and brain-derived neurotrophic factor (ng/mL) configuration on the day of treatment initiation from each patient's blood was collected from a female venous sample. After rehabilitation, patients scored lower in both depression and anxiety assessments. Women had higher scores in the assessment of anxiety disorders and depression. The longer the period from the end of COVID-19 treatment to the start of rehabilitation, the higher the Generalized Anxiety Disorder Questionnaire and The Beck Depression Inventory scores. The higher the Generalized Anxiety Disorder Questionnaire and The Beck Depression Inventory scores, the lower the handgrip strength values. With increasing irisin concentration, The Beck Depression Inventory values also increased. Comprehensive rehabilitation may be associated with a reduction in the severity of anxiety and depressive symptoms in patients after COVID-19. Earlier initiation of rehabilitation may be associated with better emotional well-being in patients after COVID-19. The severity of anxiety and depressive symptoms may be associated with gender, age, and hospitalization during COVID-19 treatment. Increased irisin levels in patients after COVID-19 may be associated with inflammatory and metabolic complications after infection. However, interpretation of these relationships requires further studies taking into account additional biological variables and prospective analyses.